A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 11 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2014 Planned End Date changed from 1 Nov 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.